Prof. Roberto Iacovelli: Drug interruptions in mRCC IO-TKI (Avelumab and axitinib) is safe and may reduce toxicity and cost for the treatment
In this podcast, UROONCO RCC associate editor Dr. Teele Kuusk (GB) talks with Prof. Roberto Iacovelli (IT), Gostino Gemelli University Polyclinic, Rome, about the abstract he presented at ESMO 2023, "The TIDE-A study: Phase II study of avelumab (Ave) plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma."
Prof. Iacovelli shares details on the TIDE-A study, the first study demonstrating the potential benefits of VEGFR-TKI interruption combined with immunotherapy. Results showed decreased treatment-related toxicity and delayed tumour progression in mRCC patients. The safety of the combination of avelumab and axitinib in mRCC patients was also promising, and he suggests that future investigations in a randomised trial would be worthwhile.
Contact our organiser